Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)

The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or have an inadequate response, the U.S. market is crowded with efficacious biologics and targeted oral therapies, including blockbuster TNF-alpha inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and non-TNF-alpha inhibitors, such as Bristol Myers Squibb’s Orencia and Roche’s Actemra and the oral JAK inhibitors Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). Indeed, the FDA’s approval of Rinvoq has increased the competition in the JAK inhibitor class and among the non-TNF biologics. However, the FDA’s safety warnings regarding the JAK inhibitor class may impact overall use of the drugs, leading to greater uptake of other targeted agents. class will affect the overall use of these drugs, leading to greater uptake of other targeted agents.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed RA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed RA patients?
• How have JAK inhibitors been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of RA patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?
• What percentage of RA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs: Enbrel, Humira, Remicade, Orencia, Actemra, Olumiant, Kevzara, Rituxan, Xeljanz, Rinvoq

Key analyses: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow charts

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.